In the News: Maison MGA is driving the ENVOL project forward with Lyonbiopôle

We are proud to see our expertise highlighted by Lyonbiopôle as part of the launch of the ENVOL project, a major breakthrough for the cosmetics and pharmaceutical industries.

A technological and ethical revolution

The ENVOL project (Epidermis Neurone Vascularization On digital Library) does more than just innovate: it radically transforms biocompatibility testing. Supported by the France 2030 plan and the Auvergne-Rhône-Alpes Region, this program aims to create an ultra-realistic “skin-on-a-chip” that is both innervated and immunocompetent.

This technology allows us to obtain a precise “digital signature” of the skin’s reaction, thereby offering a reliable and ethical alternative to reduce the use of animal testing.

Our industrial expertise at the heart of the consortium

Alongside the Icare Group (project leader), the LBTI laboratory (CNRS / University of Lyon 1), and the startup Netri, we provide a key technological component.

Through our subsidiary MGA MedTech, we apply our cutting-edge engineering expertise to the design and production of:

• High-performance measurement instruments.
• Technical consumables designed for these new biological systems.

A boost for our ecosystem

This €2 million project perfectly illustrates our mission: to combine industrial innovation with health challenges to position our region as a global center of excellence.

“Participating in the ENVOL project means putting our teams’ agility to work for a more humane and precise science. We are honored by this collaboration, which is shaping the future of medical research.”